ADELAIDE, Australia--(BUSINESS WIRE)--Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a global, clinical stage biopharmaceutical company, announces that an additional data analysis conducted in Sweden by ...
BNC210 novel oral tablet formulation (900 mg given twice daily) exceeds blood exposure projected for upcoming Phase 2b PTSD trialBNC210 Phase 2b PTSD trial on target for start in mid-2021 with final ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback